Baseline lesion number as an efficacy predictive and independent prognostic factor and its joint utility with TMB for PD-1 inhibitor treatment in advanced gastric cancer.

Ther Adv Med Oncol · 2021 · PMC7871293 · PMID 33613701

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

showed a trendp > 0.05actually significant

We defined TMB > 12 (mutations/Mb) as high TMB group in consistent with our previous report, which showed a trend of better mPFS than low TMB group [HR, 0.450; CI, (0.196–1.034); p > 0.05].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.